Dr. Anthony Sabatelli, chair of Dilworth IP’s biotech and pharmaceutical patent practice group, has been appointed by CURE (Connecticut United for Research Excellence) to serve on its newly convened government affairs committee.  The committee comprises representatives from CURE’s board of directors, the pharmaceutical and bioscience sectors, and the legal community. In this new role, Dr. Sabatelli will spearhead federal outreach initiatives for CURE and will work closely with the government relations firm Rome, Smith & Lutz to assure synergy of action and alignment of state and federal initiatives.  “I look forward to working with this committee on issues of importance to the biotech and pharmaceutical industries and to being a voice for our industry here in Connecticut”, says Dr. Sabatelli.

This is the latest collaboration between Dilworth IP and CURE.  Last fall, the Firm joined CURE as a Founding Partner in its launch of the Innovation Commons, a collaborative work environment for entrepreneurs and innovators in the bioscience industry on the Pfizer campus in Groton, CT.

Further information about the committee and its initiatives can be found on the CURE website http://cureconnect.org/wp-content/uploads/2015/01/govaffair4.pdf

CURE serves as the bioscience cluster of Connecticut, a diverse community of small and large life and healthcare sciences companies, ranging in scope from therapeutics, to healthcare technology, to medical devices. Universities, government agencies, scientists, educators, mentors, students, entrepreneurs, business experts, service providers, and investors join in to form the breadth of the network. As participants in CURE, we educate, cultivate entrepreneurship, support the build of bioscience companies, and collaborate to ensure a sustainable, high-value bioscience and healthcare community that improves our quality of life and keeps the Connecticut community strong.